## Highlights of This Issue

### SPECIAL FEATURES

**How to Train Your Biomarker**
Douglas Yee  
*See article p. 3193*

**Inhibition of the PI3K Pathway: Hope We Can Believe in?**
Michiel S. van der Heijden and René Bernards

**Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway**
Laurence Zitvogel, Oliver Kepp, Laura Senovilla, Laurie Menger, Nathalie Chaput, and Guido Kroemer

**Drugs That Target the Stemness Pathways**
Susan E. Bates

**Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways**
Naoko Takebe and S. Percy Ivy

**The Difficulty of Targeting Cancer Stem Cell Niches**
Mark A. LaBarge

**Targeting Hedgehog—a Cancer Stem Cell Pathway**
Akil A. Merchant and William Matsui

**Targeting Notch to Target Cancer Stem Cells**
Antonio Pannuti, Kimberly Foreman, Paola Rizzo, Clodia Osipo, Todd Golde, Barbara Osborne, and Lucio Miele

**Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis**
Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashiha, Hisamichi Aizawa, Yuji Basaki, Michihiko Kusanagi, Masayoshi Kage, Tetsuya Mitsudomi, and Mayumi Ono

**Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2**
Gong Yang, Bin Chang, Fan Yang, Xiaqing Guo, Kathy Qi Cai, Xue (Sherry) Xiao, HuaMin Wang, Subrata Sen, Mien-Chie Hung, Gordon B. Mills, Sandy Chang, Asha S. Multani, Imelda Mercado-Uribe, and Jinsong Liu

**Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?**
Fumi Takahashi-Yanaga and Michael Kahn

## Cancer Therapy: Preclinical

**FTY720 Shows Promising *In vitro* and *In vivo* Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma**
Qing Liu, Lapo Alinari, Ching-Shih Chen, Fengting Yan, James T. Dalton, Rosa Lapalombella, Xiaoli Zhang, Rajeswaran Mani, Teresa Lin, John C. Byrd, Robert A. Baiocchi, and Natarajan Muthusamy

**Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development**
Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, Marilella Varella-Garcia, Christopher Korch, and S. Gail Eckhardt
*See commentary p. 3091*
Molecular Imaging of N-linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer Therapy
Joseph N. Contessa, Mahaveer S. Bhojani, Hudson H. Freeze, Brian D. Ross, Alnawaz Rehemtulla, and Theodore S. Lawrence

Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study
Tobias Bauerle, Maximilian Merz, Dorde Komiljnovic, Stefan Zwick, and Wolfhard Semmler

Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC
Nita Amornsiripanich, Shaolin Hong, Michael J. Campa, Michael M. Frank, Elizabeth B. Gottlin, and Edward F. Patz, Jr.

A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth
Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp-Schneider, Marc Remke, Paul Northcott, Hedwig E. Deubzer, Marco Ladrini, Michael D. Taylor, Andreas von Deimling, Stefan Pfister, and Olaf Witt

Overexpression of p73 as a Tissue Marker for High-Risk Gastritis
Gonzalo Carrasco, Jose Diaz, Jose R. Valbuena, Paulina Ibanez, Paz Rodriguez, Gabriela Araya, Carolina Rodriguez, Javiera Torres, Ignacio Duarte, Edmundo Aravena, Fernando Mena, Carlos Barrientos, and Alejandro H. Corvalan

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
María Victoria Mateos, María Teresa Cibeira, Paul G. Richardson, Felipe Prosper, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Ramón García-Sanz, Sonia Extremena, Sergio Szyldergemajn, Claudia Corrado, Harald Singer, Constantine S. Mitsiades, Kenneth C. Anderson, Joan Bladé, and Jesús San Miguel

Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants
Barbara L. Andersen, Lisa M. Thornton, Charles L. Shapiro, William B. Farrar, Bethany L. Mundy, Hae-Chung Yang, and William E. Carson III

AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
Per-Uno Malmström, Angelica S.I. Loskog, Camilla A. Lindqvist, Sara M. Mangsbo, Moa Fransson, Alkwin Wanders, Truls Gårdmark, and Thomas H. Tötterman

Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients
Delphine Kérob, Raphael Porcher, Olivier Vérola, Stephane Dalle, Eve Maubec, François Aubin, Michel D'Incan, Isaak Bodokh, Serge Boulinguez, Isabelle Madeleine-Chambrin, Anne Mathieu-Boue, Jean-Marie Servant, Eric de Kerviler, Anne Janin, Fabien Calvo, Florence Pedeutour, and Celeste Lebbe
ABOUT THE COVER

Early detection of gastric cancer requires risk assessment of premalignant conditions. The cover image shows a positive and negative representative immunostain of eight tissue markers (BRCA1, HSP90, EGFR, p73, STAT1, FHIT, p16INK4a and p53) and EBER-1 expression in tissue microarrays of early gastric cancer, nontumor adjacent mucosa, and chronic gastritis control cases, where p73 emerges and may have a potential role in the assessment of high-risk gastritis. Moreover, integration of these findings with histological features shows that overexpression of p73 is the most relevant finding. For further details, please see the article by Carrasco and colleagues on page 3253 of this issue.